Track ENGN and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
enGene Holdings Inc. Common Stock
4868 Rue Levy, Montreal, QC, Canada, H4R 2P1
IPO
2023
Employees
81
Industry
Biotechnology
Sector
Healthcare
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q4 20240+3
3
Q3 20240+3
3
Q2 20242-2
0
Q4 20230+2
2
4-quarter cumulative
2 sells8 buys
Analyst Ratings
6 analysts covering
Buy83%recommend buy
Buy
5
Hold
1
Sell
0